New Testing Update:
Starting Thursday April 2, 2020, we are now administering Covid-19 anti-body tests in the clinic with results in 20 minutes from a blood draw. At present, insurance coverage for the point of care testing is pending. If you would like this test, please call our clinic at 706-310-0324 (Watkinsville) or 706-343-4043 (Madison). The cash pay price is $60 for the test. Clinic visit fees still apply. Clinic visit fees and any other procedures will be billed to insurance. Cash/Self pay clinic office visit fee is $150.
Clinic procedures remain in place for Covid-19 patients. All patients who believe they may have Covid-19 or have been exposed will see a provider from their car. Please park your car in a parking space and call our clinic when you arrive. We will step you through the process over the phone.
In order to get COVID-19 rapid-test at Urgent Care of Oconee
Send an email to firstname.lastname@example.org and attach:
Driver’s license copy
Insurance card(s) (front/back)
New Patient Packet (4 pages all filled out).
Under "patient resources" tab on our website you can access our "new patient packet." Please type answers into the document if possible, download to your computer, and email back to us. We will accept a photo of each page if you are not able to type the answers into the document and need to instead hand-write it.
*IMPORTANT* Under the email’s subject—> please write the location in which you are getting seen at (Watkinsville or Madison), the time that you are planning on arriving, AND the car model/color you will be driving in.
Once here, give us a call once you are parked in our parking lot and we will give you further instructions and collect payment over the phone if needed.
COVID TESTING HOURS
COVID HOURS FOR NONSYMPTOMATIC PATIENTS:
Monday - Friday = 8:30am - 5:00pm
Saturday = 11:00am - 4:00pm
Sunday = 12:00pm - 4:00pm
We are testing our COVID patients outside. If bad weather becomes an issue, for the safety of our staff and patients, we will stop testing until the weather has passed.
Serology (Antibody) COVID-19 Results
The standard Q COVID-19 IgG/IgM Rapid Test is being marketed in accordance with the U.S. Food and Drug Administration's (FDA's) recent guidance, titled "Policy for Diagnostic Tests for Coronavirus Disease-2019 during the Public Health Emergency," which was issued on March 16, 2020. FDA issued this guidance to help accelerate the availability of novel coronavirus (COVID-19) diagnostic tests developed by laboratories and commercial manufacturers during the public health emergency.
*This test had not been reviewed by the FDA:
*Negative results do not rule out SARS-CoV-2 infection, particularly in those who have been in contact with the virus. Follow-up testing with molecular diagnostic should be considered to rule our infection in these individuals;
*Results from antibody testing should not be used as the sole basis to diagnose or exclude SARS-CoV-2 infection or to inform infection status;
*Positive results may be due to past or present infection with non-SARS-CoV-2 coronavirus strains, such as coronavirus HKU1, NL63, OC43, or 229E, or past or pristine infection with SARS virus (no.6). Your healthcare provider will work with you to determine how best to care for you based on the test results along with medical history, and your symptoms.
Coronavirus Disease 2019
Symptoms & Testing
Home page for COVID-19 symptoms with links to symptoms, testing and reduced stigma.
There are three types of lab testing methods/platforms available, which detect the virus in different ways:
· Viral antigen
· Host antibody tests (serology
During the rise of Viral RNA and Viral Antigen levels, a molecular (PCR or isothermal nucleic acid amplification based) or viral antigen test detects the presence of the virus. Often times, these molecular and viral antigen tests can be used as the primary basis for diagnosing your patient’s condition. Rather than going through the normal approval process, the U.S. Food and Drug Administration (FDA) is permitting all COVID-19 molecular and viral antigen tests to be cleared through its Emergency Use Authorization (EUA) process during the pandemic.
Host antibody (serology) tests detect the IgM and IgG antibodies that indicate your patient has developed an immune response to the virus. Typically, the results of these tests are not used as the sole basis for your diagnosis. Because of their complementary role, FDA is permitting COVID-19 serology tests to be brought to market without any formal FDA review (at minimum, a manufacturer must notify FDA that its test has been validated).